GlassScriptPhysician profile
Anna Maria Barbieri
NPI 1245284900
$9,162.07
in general payments reported to CMS, 2019-2025
25 companies · $7,046 in 2025
The $7,046 reported for 2025 was more than what 98% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $146 · 2021: $113 · 2022: $225 · 2023: $720 · 2024: $319 · 2025: $7,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,970 · Travel and Lodging: $1,531 · Food and Beverage: $1,273 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,970.00 |
| Travel and Lodging | $1,530.82 |
| Food and Beverage | $1,273.41 |
| Education | $310.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $6,192.82 | 2025 | |
| Astellas Pharma US INC | $908.09 | 2023-2025 | Veozah |
| Amneal Pharmaceuticals LLC | $308.00 | 2023 | |
| Abbvie INC. | $169.67 | 2019-2023 | Lo Loestrin Fe |
| Amag Pharmaceuticals, INC. | $157.66 | 2019-2020 | |
| Allergan, INC. | $135.49 | 2019 | |
| Millicent US INC | $135.32 | 2019-2025 | Intrarosa, Femring |
| Pfizer INC. | $127.30 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $126.75 | 2022-2025 | |
| Avion Pharmaceuticals | $119.59 | 2019-2023 | Divigel |
| Vertical Pharmaceuticals, LLC | $118.52 | 2019-2020 | |
| Therapeuticsmd, INC. | $109.56 | 2019-2022 | |
| Exact Sciences Corporation | $105.60 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $83.88 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $83.55 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $50.78 | 2023-2024 | Accrufer |
| Evofem Biosciences, INC. | $44.15 | 2021-2023 | Phexxi |
| Exeltis, USA INC. | $41.80 | 2019 | |
| Agile Therapeutics, INC. | $36.44 | 2021-2023 | Twirla |
| Coopersurgical, INC. | $28.35 | 2020 | |
| Daiichi Sankyo INC. | $18.42 | 2022 | |
| Lupin INC. | $17.06 | 2019 | |
| Merck Sharp & Dohme LLC | $15.28 | 2023 | Pneumovax 23, Gardasil 9, Vaxneuvance |
| Renovia INC | $14.29 | 2019 | |
| Hologic Sales and Service, LLC | $13.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Barbieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.